Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec;5(6):834-843.
doi: 10.21037/tau.2016.07.10.

Pharmacology of testosterone replacement therapy preparations

Jennifer J Shoskes  1 , Meghan K Wilson  2 , Michael L Spinner  2
Affiliations
Review

Pharmacology of testosterone replacement therapy preparations

Jennifer J Shoskes et al. Transl Androl Urol. 2016 Dec.

Abstract

The goal of testosterone replacement therapy (TRT) is to return serum testosterone levels to within physiologic range and improve symptoms in hypogonadal men. Some of the symptoms aimed to improve upon include decreased libido, erectile dysfunction, infertility, hot flashes, depressed mood, and loss of muscle mass or hair. Clinical use of testosterone for replacement therapy began approximately 70 years ago. Over the decades, numerous preparations and formulations have been developed primarily focusing on different routes of delivery and thus pharmacokinetics (PKs). Currently the routes of delivery approved for use by the United States Food and Drug Administration encompasses buccal, nasal, subdermal, transdermal, and intramuscular (IM). Many factors must be considered when a clinician is choosing the most correct formulation for a patient. As this decision depends highly on the patient, active patient participation is important for effective selection. The aim of this review is to describe and compare all testosterone preparations currently available and approved by the United States Food and Drug Administration. Areas of focus will include pharmacology, PKs, adverse effects, and specifics related to individual delivery routes.

Keywords: Drug delivery systems; hypogonadism; pharmacology; testosterone.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Molecular structure. (A) Testosterone; (B) 17α-methyltestosterone.
Figure 2
Figure 2
Molecular structure. (A) Testosterone undecanoate; (B) testosterone cypionate; (C) testosterone enanthate.
See this image and copyright information in PMC

References

    1. United States Food and Drug Administration [Internet]. Silver Spring: United States Food and Drug Administration; 2016 [updated 2005 March 3; cited 2016 Apr 25]. Available online: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa...
    1. Manni A, Pardridge WM, Cefalu W, et al. Bioavailability of albumin-bound testosterone. J Clin Endocrinol Metab 1985;61:705-10. 10.1210/jcem-61-4-705 - DOI - PubMed
    1. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59. 10.1210/jc.2009-2354 - DOI - PubMed
    1. Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004;89:5920-6. 10.1210/jc.2003-031719 - DOI - PubMed
    1. Baillargeon J, Urban RJ, Ottenbacher KJ, et al. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med 2013;173:1465-6. 10.1001/jamainternmed.2013.6895 - DOI - PMC - PubMed